Abstract-Prior studies evaluating metabolic syndrome (MetS) and incident peripheral artery disease (PAD) 
T he metabolic syndrome (MetS) is defined by a combination of criteria including elevated triglycerides, reduced high-density lipoprotein, high blood pressure, impaired fasting glucose, and increased abdominal girth. [1] [2] [3] Prevalence of the MetS has been consistently associated with incident coronary artery disease, stroke, and cardiovascular mortality. [4] [5] [6] [7] To our knowledge, there are only 2 published prospective studies evaluating associations of MetS and incident peripheral artery disease (PAD); however, both are limited by the use of clinical PAD alone as an end point. 8, 9 These studies also used modified MetS criteria by substituting the presence of diabetes mellitus for impaired fasting glucose and body mass index for increased abdominal girth. Given the moderate correlation between atherosclerosis across different vascular beds, 10 it remains uncertain whether MetS is similarly associated with PAD.
Atherogenic risk factors such as impaired fibrinolysis, oxidative stress, hypoadiponectinemia, and increased thrombogenicity often cluster with the MetS. 11, 12 Although traditional definitions of MetS incorporate measures of insulin resistance, they do not account for measures of inflammation. Inflammatory markers such as C-reactive protein (CRP) and interleukin-6 are elevated in MetS. 6, 11, 13 Some have proposed that inflammation be included into the definition of the MetS, 14 but whether inflammation provides additional information to standard MetS criteria is unclear.
The Cardiovascular Health Study (CHS) offers a unique opportunity to examine associations between MetS and incident PAD in a large, well-defined population with longterm follow-up. We investigated the association of MetS and its individual components with the risk of developing a low
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ankle-brachial index (ABI) as well as symptomatic clinical PAD. We also investigated how a modified MetS definition that includes inflammation is associated with incident PAD.
Methods

Study Participants
The CHS is a community-based, longitudinal observational study of adults ≥65 years at baseline that was designed to evaluate risk factors for the development and progression of cardiovascular disease. The study's primary objectives and design have been reported previously. 15, 16 Briefly, participants were recruited from randomly sampled Medicare eligibility lists in Sacramento, CA; Forsyth County, NC; Washington County, MD; and Allegheny County, PA. Eligibility also required an expectation to remain in the area for 3 years after recruitment, no active cancer treatment, and written informed consent. An initial 5201 individuals were recruited between 1989 and 1990, and an additional 687 blacks were recruited in 1992 and 1993. The study received approval from investigational review boards of the 4 clinical sites and the coordinating data center at the University of Washington.
Laboratory Analyses
Please refer to Methods in online-only Data Supplement.
Classification of MetS
MetS was defined as meeting 3 of the following 5 criteria consistent with the joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity 17 : (1) large waist circumference (women ≥88 cm, men ≥102 cm), (2) elevated triglycerides (≥150 mg/dL), (3) low high-density lipoprotein (men <40 mg/ dL, women <50 mg/dL), (4) impaired fasting glucose (≥100 mg/dL and <126 mg/dL), and (5) high blood pressure (≥130 and ≥85 mm Hg or use of medications for hypertension). We categorized 8 individuals who were positive for 3 or more criteria as having MetS even if information was missing on the others; these individuals were excluded in analyses of number of positive components. Use of fibrates and nicotinic acid at baseline was rare (1.8%) in this cohort and was not included in our definition. 18 Consistent with prior research evaluating an incorporated definition of inflammation and MetS, inflammation-MetS (CRP-MetS or fibrinogen-MetS) was defined as having 3 or more of 6 components, including elevated markers of inflammation as a sixth component. 19 Elevated CRP was defined as ≥3 mg/L. 19 Elevated fibrinogen corresponded to a value in the highest tertile of our study population (>341 mg/dL).
Ankle-Brachial Index
The ABI was measured according to a standard protocol by trained technicians and has been described previously. 20 After at least 5 minutes of rest and with the subject in a supine position, standard mercury sphygmomanometers and a Doppler stethoscope (8 MHz, Huntleigh Technology, Luton, United Kingdom) determined the right brachial artery and right and left leg posterior tibial artery systolic blood pressures. Repeat measurements were obtained and averaged. The correlations for each duplicate blood pressure were left leg, 0.97; right leg, 0.97; and right arm, 0.95. 21 The left arm was used if the blood pressure could not be measured adequately in the right arm. The ratio of the systolic blood pressure in the leg to the arm defined the leg-specific ABI. The lower of the leg-specific ABIs was used as the patient-specific ABI. When arterial flow was not abolished with the leg blood pressure cuff inflated to >300 mm Hg, the artery was deemed incompressible.
To determine the change in ABI with similar follow-up time for both enrollment cohorts, we used ABI determination in the index leg from participants who had an ABI measured in 1992 to 1993 and in 1998 to 1999. ABI decline was defined as the difference between ABI at baseline and in the same leg in 1998 to 1999 (baseline minus follow-up). Incident low ABI was defined as a decline in ABI of at least 0.15 to 0.9 or less. Requiring a decline of at least 0.15 is consistent with definitions used in prior CHS articles, can help to limit regression to the mean, and avoids small, clinically insignificant changes being included in the incident low ABI definition.
22,23
Clinical PAD
At baseline, clinical PAD was defined as either an ABI <0.90 at the baseline examination or both exertional leg pain relieved by rest and a physician's diagnosis of PAD. In addition, any of the following also validated a PAD diagnosis, with evidence that the test was initiated by the participant's complaint of leg pain: Doppler ultrasound showing at least a 75% reduction in the cross-sectional area of the artery or showing an ulcerated plaque; angiography showing at least a 50% reduction in the diameter or 75% reduction in the cross-sectional area of the artery or showing an ulcerated plaque; absence of a Doppler pulse in any major vessel; a positive exercise test for claudication; or bypass surgery, angioplasty, amputation, or thrombolysis for the indication of PAD. During follow-up, potential incident clinical PAD was identified by self-report of a PAD diagnosis by the participant at an annual clinic visit or during a 6-month follow-up telephone call, a PAD diagnosis found during review of medical records for other events, or as part of regular review of Centers for Medicare & Medicaid Services records for the International Classification of Diseases, ninth revision codes 440.2 (atherosclerosis of the native arteries of the extremities) and 443.9 (peripheral vascular disease, unspecified). After a potential PAD event was identified, medical records were then reviewed, and a final decision was adjudicated by the Morbidity Subgroups of the CHS Clinical Events Subcommittee.
Other Covariates
Analytic Cohorts
Because diabetes mellitus is a known strong predictor of incident PAD, we excluded participants with diabetes mellitus to evaluate the separate influence of MetS on PAD incidence per se. 22, 24 Different analytic cohorts were used for the 2 outcomes of incident low ABI and clinical PAD. The analysis of incident clinical PAD events used date of enrollment as baseline. Of the 5888 participants enrolled in CHS, we excluded 151 with prevalent PAD, 50 who were missing data on more than 2 MetS components, 68 who were missing measurements on CRP or fibrinogen, 867 with diabetes mellitus, and 120 who were missing covariate information. A total of 4632 participants were therefore available for the analysis of clinical PAD. The analysis of incident low ABI included participants who had an ABI measured in 1992 to 1993 and in 1998 to 1999 and used the 1992-1993 examination as baseline ( Figure) .
Statistical Analysis
Incident Low ABI
We used general linear models with log link, Poisson error structure, and robust standard errors to calculate relative risks for developing a low ABI according to the presence or absence of MetS, each MetS component, and each inflammatory marker. Models were adjusted for age, sex, race, clinic site, alcohol consumption, cigarette smoking (current status and pack-years of smoking), prevalent cardiovascular disease, low-density lipoprotein, estimated glomerular filtration rate (eGFR), and physical activity levels. Prevalent cardiovascular disease was defined as history of myocardial infarction, angina, angioplasty, bypass surgery, or stroke. Models evaluating the presence or absence of MetS were additionally adjusted for CRP and fibrinogen. To evaluate whether the association of MetS and PAD was modified by either sex or race, we fit models that included cross-product terms and tested the statistical significance of these terms.
To evaluate whether the risk of low ABI varied according to the number of MetS components present, we categorized participants by the number of MetS components at baseline and estimated the To assess the individual and joint associations of MetS and inflammation markers with incident low ABI, we cross-classified participants on MetS status (presence/absence) and inflammation status (low/high). CRP and fibrinogen were considered separately and low/ high categories were dichotomized at 3 mg/L for CRP and the highest tertile of the distribution for fibrinogen (341 mg/dL). We calculated the relative risk of incident ABI for each category compared with the group without MetS and low inflammation levels.
Finally, adjusted relative risks were calculated incorporating CRP or fibrinogen into the MetS definition (CRP-MetS and fibrinogenMetS) to determine whether this improves risk prediction of a low ABI. A c-statistic (area under the receiver operating characteristic curve) of the modified MetS definition for a low ABI was also calculated to determine the added impact of inflammatory markers.
Incident Clinical PAD
To evaluate the association between MetS, individual MetS components, inflammatory markers, and incident clinical PAD, we calculated hazard ratios (HRs) and 95% confidence interval (CI) using Cox proportional hazards models. Participants who did not develop clinical PAD were censored at the earliest of loss to follow-up, death, or the end of follow-up for this analysis (June 2007), and time-to-event was calculated as the interval between enrollment and either incident PAD or censorship.
Results
Baseline characteristics of participants followed up for clinical PAD stratified by the presence or absence of MetS are shown in Table 1 .
There were 253 cases of incident low ABI among the 1899 participants with follow-up ABI measurements. There were 208 incident cases of clinical PAD among the 4632 participants followed up for this outcome over a median duration of 13.7 years. Of the individual MetS criteria, only high blood pressure was significantly associated with the development of both a low ABI and clinical PAD (Table 2) , although impaired fasting glucose was nearly so. In a multivariable model including all individual MetS criteria and both inflammatory markers, hypertension remained significantly associated with the development of both a low ABI (RR, 2.07; 95% CI, 1.49-2.86) and clinical PAD (HR, 2.11; 95% CI, 1.40-3.17), CRP remained significantly associated with developing clinical PAD (HR, 1.68; 95% CI, 1.24-2.27), and fibrinogen remained significantly associated with an incident low ABI (RR, 1.41; 95% CI, 1.11-1.81). Compared with individuals with no baseline MetS criteria, the relative risk of incident low ABI increased with increasing number of MetS criteria (Table S1 in the online-only Data Supplement). 
Incorporating Inflammation With MetS on Risk of
Discussion
In a cohort of community-dwelling older adults, MetS was associated with the development of PAD, defined either by a low ABI or the development of clinically manifest PAD, after the adjustment for traditional risk factors and markers of inflammation. Hypertension was the only MetS component independently associated with incident PAD. Inflammatory markers CRP and fibrinogen were also independently associated with incident PAD.
Our findings contrast with the 2 previously published studies on the prospective associations of MetS and incident PAD. The Edinburgh Artery Study (EAS) found no association between MetS and incident PAD. 8 In the Women's Health Study, a younger cohort of females free of baseline cardiovascular disease participating in a clinical trial, MetS was associated with an increased risk of incident PAD. 9 This association, however, was strongly attenuated after adjustment for inflammatory markers CRP and soluble intracellular adhesion molecule-1 and no longer significant.
The CHS cohort comprised older individuals with a significantly higher baseline prevalence of hypertension and may, in part, explain discrepancies between our findings and those reported in the EAS and Women's Health Study. Additionally, these 2 prior studies used adapted definitions of MetS and, consequently, did not capture the true prevalence of participants meeting criteria for this syndrome. Waist circumference was not available in either study and body mass index was used instead, which may not capture visceral adiposity. In addition, the Women's Health Study defined glucose intolerance as the presence or absence of diabetes mellitus, and diabetes mellitus is a well-established PAD risk factor. 9 Thus, overt diabetes mellitus may have driven associations in this study. Additionally, the primary end point for both studies was limited to symptomatic PAD. Prior studies have reported that anywhere from 20% to 50% of individuals with PAD are asymptomatic. 25, 26 The presence of PAD as assessed by ABI as we did here, regardless of the presence of symptoms, is strongly associated with increased cardiovascular morbidity and mortality. 27 It is unclear why these findings were not consistent across race. Our null findings in black participants may simply be the result of small event numbers or chance. Further study with primary attention to racial differences is needed.
The association between inflammation and incident PAD has been demonstrated previously. 28 Both CRP and fibrinogen have been reported to be associated with the development of incident PAD. 28, 29 Our results corroborate those of prior studies by also showing an independent association between inflammation and the development of PAD. It is unclear, however, why CRP was only significant for the development of clinical PAD and fibrinogen only significant for the development of a low ABI. As mentioned previously, the CHS cohort is different at baseline from other well-studied cohorts in terms of age and prevalence of hypertension. As a result, it may be that different biomarkers are relevant in different populations. Alternatively, these results may signify that inflammation is important in development of both outcomes, and the disparity found between fibrinogen and CRP is simply reflective of chance.
To our knowledge, this is the first prospective study to evaluate the incorporation of inflammation markers into a MetS definition with incident PAD. Findings from the Women's Health Study suggested that increased inflammation and endothelial activation might serve as a mechanistic link between MetS and incident PAD. Our results suggest that the relationship between MetS and incident PAD is independent of common inflammatory pathways represented by markers such as CRP and fibrinogen, but the addition of inflammation to the definition of MetS identified larger numbers of older adults at risk and, at least for MetS-Fib, significantly improved discrimination between individuals who did and did not develop a low ABI.
Hypertension was the only MetS component independently associated with incident PAD. Prior studies have documented a strong cross-sectional association between hypertension and PAD. 25, 30 In CHS participants, hypertension was previously reported as a risk factor for ABI decline. 22 eGFR has been previously reported to be closely correlated to hypertension in CHS participants and may explain why findings were slightly attenuated after adjusting for this. 31 It is also possible that eGFR may be a mediator. Our findings underscore the particular role of hypertension in the development of PAD in older individuals with MetS. Current American College of Cardiology and American Heart Association guidelines recommend all individuals aged ≥65 years be screened for PAD. Because hypertension is extremely prevalent and a strong risk factor for PAD development in older age, our results only further justify the need to screen all individuals aged >65 years Our study has limitations. The CHS participants are all aged ≥65 years; therefore, our results may not be generalizable to younger aged cohorts. Follow-up ABI data were not available for many participants, and this may have introduced bias to analyses involving ABI decline, although results were generally similar for analyses of incident clinical PAD that were not limited by attrition. 
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